References
- Parkin DM, Bray FJ, Pisani P. Global cancer statistics. CA. 2002;2005–74.
- Group MCOCW. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.
- Hagen PV, Hulshof MCCM, Lanschot JJBV, Steyerberg EW, Henegouwen MIVB, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. J Med Imag Radiat On. 2012;43:215–9.
- Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, CROSS study group, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8., doi:https://doi.org/10.1016/S1470-2045(15)00040-6
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi:https://doi.org/10.3322/caac.20006
- Cohen DJ, Jaffer A. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011;12(2):225–39. doi:https://doi.org/10.1517/14656566.2010.517748
- Siersema PD. Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Curr Opin Gastroen. 2007;23:456.
- Visser E, Franken IA, Brosens LAA, Ruurda JP, Hillegersberg RV. Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget. 2017;8(3):5566–77. doi:https://doi.org/10.18632/oncotarget.13328
- Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin Cancer Biol. 2013;23(6 Pt B):512–21. doi:https://doi.org/10.1016/j.semcancer.2013.08.005
- Zheng Q, Chen C, Guan H, Kang W, Yu C. Prognostic role of microRNAs in human gastrointestinal cancer: a systematic review and meta-analysis. Oncotarget. 2017;8(28):46611–23. doi:https://doi.org/10.18632/oncotarget.16679
- Anna S, Shenouda NS, Sakla MS, Drenkhahn SK, Narula AS, Macdonald RS, Besch-Williford CL, Lubahn DB. Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res. 2010;70(8):3382–90. doi:https://doi.org/10.1158/0008-5472.CAN-09-3012
- Mònica C, Desirée C, Saleta S, Isabel B, Jordi X, Julio G, Antonio Z. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2010;35:584–92.
- Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. Cancer Lett. 2008;269(2):315–25. doi:https://doi.org/10.1016/j.canlet.2008.03.046
- Zhao S, Jiang Y, Zhao J, Li H, Yin X, Wang Y, Xie Y, Chen X, Lu J, Dong Z, et al. Quercetin-3-methyl ether inhibits esophageal carcinogenesis by targeting the AKT/mTOR/p70S6K and MAPK pathways. Mol Carcinog. 2018;57(11):1540–52. doi:https://doi.org/10.1002/mc.22876
- Chen KC, Hsu WH, Ho JY, Lin CW, Chu CY, Kandaswami CC, Lee MT, Cheng CH. Flavonoids Luteolin and Quercetin Inhibit RPS19 and contributes to metastasis of cancer cells through c-Myc reduction. J Food Drug Anal. 2018;26(3):1180–91. doi:https://doi.org/10.1016/j.jfda.2018.01.012
- Yang L, Liu Y, Wang M, Qian Y, Dong X, Gu H, Wang H, Guo S, Hisamitsu T. Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis. Mol Med Rep. 2016;14(5):4559–66. doi:https://doi.org/10.3892/mmr.2016.5818
- Ahmed Youness R, Amr Assal R, Mohamed Ezzat S, Zakaria Gad M, Abdel Motaal A. A methoxylated quercetin glycoside harnesses HCC tumor progression in a TP53/miR-15/miR-16 dependent manner. Nat Prod Res. 2020;34(10):1475–80. doi:https://doi.org/10.1080/14786419.2018.1509326
- Nwaeburu CC, Bauer N, Zhao Z, Abukiwan A, Gladkich J, Benner A, Herr I. Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Oncotarget. 2016;7(36):58367–80. doi:https://doi.org/10.18632/oncotarget.11122
- Zhang C, Hao Y, Sun Y, Liu P. Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis. J Pharmacol Sci. 2019;140(2):128–36. doi:https://doi.org/10.1016/j.jphs.2019.03.005
- Lu X, Chen D, Yang F, Xing N. Quercetin Inhibits Epithelial-to-Mesenchymal Transition (EMT) process and promotes apoptosis in prostate cancer via downregulating lncRNA MALAT1. Cancer Manag Res. 2020;12:1741–50. doi:https://doi.org/10.2147/CMAR.S241093
- Li Q, Dai Z, Xia C, Jin L, Chen X. Suppression of long non-coding RNA MALAT1 inhibits survival and metastasis of esophagus cancer cells by sponging miR-1-3p/CORO1C/TPM3 axis. Mol Cell Biochem. 2020;470(1–2):165–74. doi:https://doi.org/10.1007/s11010-020-03759-x
- Agostini M, Ganini C, Candi E, Melino G. The role of noncoding RNAs in epithelial cancer. Cell Death Discov. 2020;6:13. doi:https://doi.org/10.1038/s41420-020-0247-6
- Jung E, Choi J, Kim JS, Han TS. MicroRNA-based therapeutics for drug-resistant colorectal cancer. Pharmaceuticals (Basel). 2021;14(2):136. doi:https://doi.org/10.3390/ph14020136
- Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the pathogenesis of hepatocellular carcinoma: a review. Cancers (Basel). 2021;13–514. doi:https://doi.org/10.3390/cancers13030514
- Deng P, Li K, Gu F, Zhang T, Zhao W, Sun M, Hou B. LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis. Mol Med. 2021;27(1):9. doi:https://doi.org/10.1186/s10020-020-00259-y
- Liu PJ, Chen YH, Tsai KW, Yeah HY, Yeh CY, Tu YT, Yang CY. Involvement of microRNA-1-FAM83A axis dysfunction in the growth and motility of lung cancer cells. Int J Mol Sci. 2020;21–8833.
- Tao S, Li H, Ma X, Ma Y, He J, Gao Y, Li J. Elevating microRNA-1-3p shuttled by cancer-associated fibroblasts-derived extracellular vesicles suppresses breast cancer progression and metastasis by inhibiting GLIS1. Cancer Gene Ther. 2021;28(6):634–48. doi:https://doi.org/10.1038/s41417-020-00244-x
- Yang L, Hong Q, Xu SG, Kuang XY, Di GH, Liu GY, Wu J, Shao ZM, Yu SJ. Downregulation of transgelin 2 promotes breast cancer metastasis by activating the reactive oxygen species/nuclear factor‑κB signaling pathway. Mol Med Rep. 2019;20(5):4045–258. doi:https://doi.org/10.3892/mmr.2019.10643
- Shi J, Ren M, She X, Zhang Z, Zhao Y, Han Y, Lu D, Lyu L. Transgelin-2 contributes to proliferation and progression of hepatocellular carcinoma via regulating Annexin A2. Biochem Biophys Res Commun. 2020;523(3):632–8. doi:https://doi.org/10.1016/j.bbrc.2020.01.028
- Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma M, Liu JF. The tumor-suppressive function of miR-1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol. 2016;31(2):384–93. doi:https://doi.org/10.1111/jgh.13180
- Tang Y, Liu JH, Shi ZX, Li Z, Liu HT, Lu P. MicroRNA-133b suppresses cell proliferation and invasion of esophageal squamous cell carcinoma via downregulating TAGLN2 expression. Zhonghua Zhong Liu Za Zhi. 2019;41:91–6.